Abstract
The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4 imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. Some miR-181c target genes such as PBX3, HSP90B1, NMT2 and RAD21 have been associated with drug response.
Highlights
The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers
In most of the patients, the ABL tyrosine kinase of the fusion protein is effectively inhibited by the tyrosine kinase inhibitors (TKIs), but some patients are resistant to TKI therapy
To understand which miRNAs are associated with the TKI therapy response, we performed miRNA microarray in 9 bone marrow core biopsies derived from 9 Chronic myeloid leukemia (CML) patients at diagnosis including 5 imatinib-responder and 4 imatinib-resistant patients
Summary
The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. Whereas the BCR-ABL fusion drives the initial chronic phase of the disease, the progression of CML involves additional genomic changes which make leukemia cells resistant to TKI therapy and independent of BCR-ABL. To understand which miRNAs are associated with the TKI therapy response, we performed miRNA microarray in 9 bone marrow core biopsies derived from 9 CML patients at diagnosis including 5 imatinib-responder and 4 imatinib-resistant patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.